Milnacipran: Drug Profile and Safety Information

What is Milnacipran?

Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant medication that affects neurotransmitter levels in the brain. It belongs to the same class of medications as duloxetine and venlafaxine, working to increase concentrations of both serotonin and norepinephrine. In the United States, milnacipran is primarily approved for treating fibromyalgia, while in other countries it may also be prescribed for major depressive disorder.

Uses

Milnacipran has several documented therapeutic applications:

• Fibromyalgia: The primary FDA-approved indication, helping to reduce widespread pain, tenderness, and fatigue associated with this chronic condition
• Major depressive disorder: Used in some countries outside the United States to treat depression by correcting neurotransmitter imbalances
• Chronic pain conditions: May be prescribed off-label for certain types of chronic pain that involve nerve dysfunction
• Neuropathic pain: Sometimes used to manage nerve-related pain conditions due to its effects on pain-processing pathways

How it works

Milnacipran works by blocking the reuptake transporters for both serotonin and norepinephrine in the brain, preventing these neurotransmitters from being rapidly cleared from synapses. This dual action increases the availability of both chemicals, which play crucial roles in mood regulation and pain processing. The medication’s effects on these neurotransmitter systems help explain its effectiveness in both depression and chronic pain conditions like fibromyalgia.

Side effects

Common side effects include:

Submit Your Paper

• Nausea and vomiting
• Headache
• Dizziness
• Insomnia or sleep disturbances
• Constipation
• Hot flashes
• Increased sweating
• Dry mouth

Serious side effects that require immediate medical attention:

• Suicidal thoughts or behavior, especially in young adults
• Serotonin syndrome (confusion, rapid heart rate, high fever, muscle rigidity)
• Severe allergic reactions with difficulty breathing or swelling
• Abnormal bleeding or bruising
• Significant changes in blood pressure or heart rate

Warnings and precautions

• Suicide risk: Like all antidepressants, milnacipran carries a black box warning for increased suicide risk in children, adolescents, and young adults under 25, particularly during the first few months of treatment
• Pregnancy considerations: Classified as pregnancy category C; use during pregnancy should only occur when potential benefits justify potential risks to the fetus
• Kidney function: Dosage adjustments may be necessary for patients with moderate to severe kidney impairment, as the drug is primarily eliminated through the kidneys
• Heart conditions: Should be used cautiously in patients with heart rhythm disorders or uncontrolled high blood pressure due to potential cardiovascular effects
• Abrupt discontinuation: Should not be stopped suddenly due to risk of withdrawal symptoms; gradual tapering under medical supervision is recommended

Interactions

Milnacipran can interact with numerous medications and substances:

• MAO inhibitors: Dangerous interaction that can cause serotonin syndrome; must not be used within 14 days of MAO inhibitor therapy
• Other serotonergic drugs: Increased risk of serotonin syndrome when combined with SSRIs, triptans, or tramadol
• Blood thinners: May increase bleeding risk when combined with warfarin, aspirin, or other anticoagulants
• Digoxin: Can increase digoxin levels, requiring careful monitoring of heart function
• Lithium: May increase risk of serotonin syndrome and requires close monitoring
• NSAIDs: Combination may increase bleeding risk and reduce kidney function
• Alcohol: Should be avoided as it may worsen side effects and reduce medication effectiveness
• St. John’s Wort: Herbal supplement that may increase serotonin syndrome risk

Check interactions with the GMJ Interaction Checker

Dosage

For fibromyalgia in adults, milnacipran is typically started at 12.5 mg once daily for the first day, then increased to 25 mg twice daily (50 mg total) for days 2-7. The dose is then gradually increased to the recommended maintenance dose of 50 mg twice daily (100 mg total daily). Some patients may benefit from doses up to 200 mg per day, divided into two doses. Dosage adjustments are necessary for patients with kidney impairment. All dosing decisions should be individualized and determined by a qualified healthcare provider based on the patient’s specific condition, response to treatment, and other medical factors.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).